Mode of action: Firocoxib is a non-steroidal anti-inflammatory drug
(NSAID) that acts by selective inhibition of cyclooxygenase-2 (COX-2)
mediated prostaglandin synthesis. COX-2 is the isoform of the enzyme
that has been postulated to be primarily responsible for the synthesis
of prostanoid mediators of pain, inflammation, and fever. In in-vitro
equine whole blood assays, firocoxib exhibited 222 to 643 fold
selectivity for COX-2 over COX-1.

Indications : In horses: alleviation of pain and inflammation associated
with osteoarthritis and reduction of associated lameness.
Amounts to be administered and administration route: Oral use.
Administer one tablet once daily for horses weighing 450-600 kg
bodyweight. Duration of treatment will be dependent on the response
observed but should not exceed 14 days.

Advice on correct administration: One tablet should be administered with
a small amount of food in a bucket or direct by hand, presenting the
tablet combined with a small amount of food or with a treat in the palm
of the hand. After administration, it is recommended to examine the
buccal cavity to ensure that the tablet has been adequately swallowed.

Contraindications: do not use in animals suffering from gastrointestinal
disorders and haemorrhage, impaired hepatic, cardiac or renal function
and bleeding disorders. Do not use in breeding, pregnant or lactating
-animals. Do not use concomitantly with corticosteroids or other non
steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of
hypersensitivity to the active substance or to any of the excipients.

Adverse reactions: lesions (erosion
ulceration) of the oral mucosa and
of the skin around the mouth were very commonly observed in treated
animals during tolerance studies. These lesions were mild and resolved
without treatment. Salivation and labial and tongue oedema have been
uncommonly associated with the oral lesions in a field study. The
frequency of adverse reactions is defined using the following
convention: very common (more than 1 in 10 animals treated displaying
adverse reaction(s), common (more than 1 but less than 10 animals in 100
animals treated), uncommon (more than 1 but less than 10 animals in
1,000 animals treated), rare (more than 1 but less than 10 animals in
10,000 animals treated), very rare (less than 1 animal in 10,000
animals, including isolated reports treated). If you notice any side
effects, even those not already listed in this package leaflet or you
think that the medicine has not worked, please inform your veterinary
surgeon.

Detection time: 14 days

Withdrawal period: Meat and offal: 26 days. Not authorized for use in
animals producing milk for human consumption.

Presentation: 1 cardboard box containing 60 tablets in a 30 ml bottle.

Dispensing classification of the drug: POM-V.

Further information is available on request. Use medicines responsibly."

£1.62